Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedSep 11, 2026
DataAggregated Company Financials
Companies20
  • 7D-4.9%
  • 3M1.9%
  • 1Y-15.0%
  • YTD-11.6%

Over the last 7 days, the Healthcare industry has dropped 4.3%, driven by a pullback from Novo Nordisk of 4.2%. On the other hand ChemoMetec is actually up 6.9%. However, the industry is down 15% over the past year. Looking forward, earnings are forecast to grow by 4.3% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 11 Sep 2026DKK 1.7tDKK 468.2bDKK 137.3b22.3x12.5x3.7x
Sun, 09 Aug 2026DKK 1.8tDKK 472.1bDKK 141.4b22.6x12.7x3.8x
Tue, 07 Jul 2026DKK 1.9tDKK 469.1bDKK 147.1b20.7x12.6x4x
Thu, 04 Jun 2026DKK 1.6tDKK 468.7bDKK 147.0b19.3x11x3.4x
Sat, 02 May 2026DKK 1.6tDKK 447.4bDKK 129.9b18.6x12.4x3.6x
Mon, 30 Mar 2026DKK 1.4tDKK 447.8bDKK 130.1b16.6x10.9x3.2x
Wed, 25 Feb 2026DKK 1.5tDKK 447.7bDKK 131.0b18.7x11.6x3.4x
Fri, 23 Jan 2026DKK 2.3tDKK 453.8bDKK 136.9b18.7x16.5x5x
Sun, 21 Dec 2025DKK 1.9tDKK 453.8bDKK 136.9b16.9x13.7x4.1x
Tue, 18 Nov 2025DKK 1.9tDKK 454.1bDKK 137.0b17.1x13.8x4.2x
Thu, 16 Oct 2025DKK 2.1tDKK 447.6bDKK 141.7b18.3x15x4.7x
Sat, 13 Sep 2025DKK 2.0tDKK 447.3bDKK 141.7b19.9x14.4x4.6x
Mon, 11 Aug 2025DKK 1.9tDKK 434.8bDKK 132.5b28.7x14.2x4.3x
Wed, 09 Jul 2025DKK 2.5tDKK 423.0bDKK 124.5b30.7x19.7x5.8x
Fri, 06 Jun 2025DKK 2.6tDKK 423.7bDKK 124.6b30.8x20.7x6.1x
Sun, 04 May 2025DKK 2.5tDKK 409.3bDKK 121.3b23x20.6x6.1x
Tue, 01 Apr 2025DKK 2.6tDKK 409.5bDKK 121.3b23.1x21.1x6.2x
Thu, 27 Feb 2025DKK 3.4tDKK 410.0bDKK 121.4b28.8x28x8.3x
Sat, 25 Jan 2025DKK 3.3tDKK 387.4bDKK 111.3b29.4x29.8x8.6x
Mon, 23 Dec 2024DKK 3.1tDKK 387.4bDKK 111.3b28.7x28.2x8.1x
Wed, 20 Nov 2024DKK 3.8tDKK 387.3bDKK 111.3b32.1x33.8x9.7x
Fri, 18 Oct 2024DKK 4.2tDKK 372.1bDKK 107.2b37.3x39.2x11.3x
Sun, 15 Sep 2024DKK 4.7tDKK 372.0bDKK 107.1b36x43.8x12.6x
Tue, 13 Aug 2024DKK 4.6tDKK 370.3bDKK 107.0b36.1x42.6x12.3x
Thu, 11 Jul 2024DKK 4.9tDKK 355.3bDKK 106.2b35.6x46.3x13.9x
Sat, 08 Jun 2024DKK 4.9tDKK 355.3bDKK 106.2b36.2x46.5x13.9x
Mon, 06 May 2024DKK 4.3tDKK 354.8bDKK 106.4b33.9x40.9x12.3x
Wed, 03 Apr 2024DKK 4.5tDKK 341.2bDKK 99.6b38.4x44.7x13.1x
Fri, 01 Mar 2024DKK 4.2tDKK 340.1bDKK 98.9b38.2x42.9x12.5x
Sun, 28 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b34.7x42x11.8x
Tue, 26 Dec 2023DKK 3.6tDKK 320.4bDKK 90.0b32.8x40.2x11.3x
Thu, 23 Nov 2023DKK 3.6tDKK 320.5bDKK 90.0b32.7x40.4x11.4x
Sat, 21 Oct 2023DKK 3.5tDKK 305.5bDKK 82.2b27.8x42.6x11.5x
Mon, 18 Sep 2023DKK 3.5tDKK 305.5bDKK 82.2b36.6x42.9x11.5x
Price to Earnings Ratio

42.9x


Total Market Cap: DKK 3.5tTotal Earnings: DKK 82.2bTotal Revenue: DKK 305.5bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 27.5x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 12.6x which is lower than its 3-year average PE of 27.5x.
  • The 3-year average PS ratio of 8.0x is higher than the industry's current PS ratio of 3.7x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 19% per year over the last three years.
  • Revenues for these companies have grown 15% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market-2.17%
Healthcare-4.93%
Healthtech-0.58%
Medical Equipment-4.38%
Pharma-4.91%
Life Sciences-5.13%
Biotech-5.77%
Healthcare Services-10.07%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry, which is trading close to its 3-year average PE ratio of 32.7x.
    • Analysts are expecting annual earnings growth of 18.3%, which is higher than its past year's earnings growth of 9.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 113% over the next 5 years.
  • In contrast, the Pharma industry is expected to see its earnings growth to stay flat over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
CHEMM ChemoMetecDKK 522.501.2%
+DKK 104.4m		-3.6%PE51.4x
BIOPOR BioPortoDKK 1.182.2%
+DKK 12.4m		-9.6%PS15.2x
VIRO ViroGatesDKK 10.903.8%
+DKK 3.7m		12.4%PS10.8x

Latest News

CHEMM
DKK 522.50
ChemoMetec
7D
1.2%
1Y
-3.6%
GMAB
DKK 2,083.00
Genmab
7D
-5.2%
1Y
14.4%
Narrative Update • Sep 07

GMAB: Pipeline Progress Will Address Darzalex Cliff And Support 2026 Catalysts

Genmab's updated analyst fair value moves from DKK 2,392 to DKK 2,454 as analysts lift price targets toward DKK 2,500 on expectations that the broader pipeline can help manage the Darzalex patent cliff, while recent trial readouts support using a lower future P/E multiple and slightly more cautious revenue growth and margin assumptions. Analyst Commentary Recent commentary on Genmab shows a clear tilt toward optimism, with several bullish analysts lifting price targets in both DKK and US$ terms and highlighting progress across the pipeline.
ZEAL
DKK 284.20
Zealand Pharma
7D
-8.5%
1Y
-33.9%
Narrative Update • Sep 07

ZEAL: Obesity Pipeline Execution And Funding Strength Will Drive Future Upside

Zealand Pharma's narrative fair value estimate has been trimmed by about DKK 24 to DKK 433. Analysts point to a mix of lower price targets from JPMorgan and others, offset by Wells Fargo's higher DKK 420 view and updated assumptions for revenue growth, profit margins and future P/E levels.
NOVO B
DKK 286.30
Novo Nordisk
7D
-5.1%
1Y
-17.2%
COLO B
DKK 432.80
Coloplast
7D
-6.7%
1Y
-29.6%
GUBRA
DKK 319.40
Gubra
7D
-14.4%
1Y
-18.5%
New Narrative • Sep 04

Obesity And Metabolic Tailwinds Will Drive Powerful Long Term Upside Potential

Catalysts About Gubra Gubra focuses on peptide drug discovery, obesity and metabolic disease research, supported by an in-house CRO and venture investment platform. What are the underlying business or industry changes driving this perspective?
AMBU B
DKK 66.15
Ambu
7D
-5.4%
1Y
-31.2%
Narrative Update • Sep 03

AMBU B: Maintained Margin Guidance May Support Repricing Despite Recent Downgrades

Analysts have trimmed their fair value estimate for Ambu stock from DKK 88.80 to DKK 85.20, reflecting updated assumptions around revenue growth, profit margins and rising competition cited in recent research downgrades. Analyst Commentary Recent analyst moves on Ambu underline a more cautious stance, with two downgrades since early 2025 and a lower fair value estimate now embedded in expectations.
BAVA
DKK 203.60
Bavarian Nordic
7D
-7.2%
1Y
-13.2%
BIOPOR
DKK 1.18
BioPorto
7D
2.2%
1Y
-9.6%
ALK B
DKK 199.20
ALK-Abelló
7D
-4.8%
1Y
-2.9%
VIRO
DKK 10.90
ViroGates
7D
3.8%
1Y
12.4%